Literature DB >> 14615381

Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors.

J Michael Soucie1, Christy Cianfrini, Robert L Janco, Roshni Kulkarni, Julie Hambleton, Bruce Evatt, Angela Forsyth, Sue Geraghty, Keith Hoots, Tom Abshire, Randall Curtis, Ann Forsberg, Heather Huszti, Margaret Wagner, Gilbert C White.   

Abstract

Chronic joint disease from repeated bleeding into joints is a serious complication of hemophilia. To measure the extent of and to identify risk factors for deviations from normal in joint range of motion (ROM), we used cross-sectional data collected from 4343 males with hemophilia aged 2 to 19 years who received care at 136 US hemophilia treatment centers (HTCs). Factors examined included age, race/ethnicity, family history, insurance status, age at diagnosis and first HTC visit, frequency of HTC visits, hemophilia type, bleeding frequency, prophylaxis use, inhibitor status, body mass index (BMI), and recent orthopedic procedures. Trained personnel using a standard protocol obtained ROM measurements on 10 joints (hips, knees, shoulders, elbows, and ankles). Analyses used multiple linear regression to model overall ROM limitation separately by disease severity. For persons in all severity groups, joint ROM limitation was positively associated with older age, nonwhite race, and increased BMI. For those with severe disease, ROM limitation was also positively associated with number of bleeds and was greater for those with inhibitors or recent orthopedic procedures. We conclude that ROM limitations begin at an early age, especially for those with severe and moderate disease, and that BMI is an important, potentially modifiable risk factor.

Entities:  

Mesh:

Year:  2003        PMID: 14615381     DOI: 10.1182/blood-2003-05-1457

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

1.  Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis Trial.

Authors:  Margaret V Ragni
Journal:  Expert Rev Hematol       Date:  2011-10       Impact factor: 2.929

Review 2.  Von Willebrand disease in the United States: a perspective from Wisconsin.

Authors:  Veronica H Flood; Joan Cox Gill; Kenneth D Friedman; Daniel B Bellissimo; Sandra L Haberichter; Robert R Montgomery
Journal:  Semin Thromb Hemost       Date:  2011-11-18       Impact factor: 4.180

Review 3.  Key issues in inhibitor management in patients with haemophilia.

Authors:  Keith Gomez; Robert Klamroth; Johnny Mahlangu; Maria E Mancuso; María E Mingot; Margareth Castro Ozelo
Journal:  Blood Transfus       Date:  2013-12-03       Impact factor: 3.443

4.  6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

5.  Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product.

Authors:  Teruhisa Fujii; Hideji Hanabusa; Midori Shima; Takeshi Morinaga; Katsuyuki Fukutake
Journal:  Int J Hematol       Date:  2016-11-10       Impact factor: 2.490

6.  Delays in maturation among adolescents with hemophilia and a history of inhibitors.

Authors:  Sharyne M Donfield; Henry S Lynn; Alice E Lail; W Keith Hoots; Erik Berntorp; Edward D Gomperts
Journal:  Blood       Date:  2007-08-22       Impact factor: 22.113

7.  Prevalence of clinical hip abnormalities in haemophilia A and B: an analysis of the UDC database.

Authors:  D Kelly; Q C Zhang; J M Soucie; M Manco-Johnson; D Dimichele
Journal:  Haemophilia       Date:  2012-12-17       Impact factor: 4.287

8.  The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B.

Authors:  J Michael Soucie; Paul E Monahan; Roshni Kulkarni; Barbara A Konkle; Marshall A Mazepa
Journal:  Blood Adv       Date:  2018-08-28

9.  Similarity in joint function limitation in Type 3 von Willebrand's disease and moderate haemophilia A.

Authors:  S L Sood; A Cuker; C Wang; A D Metjian; E Y Chiang; J M Soucie; B A Konkle
Journal:  Haemophilia       Date:  2013-03-28       Impact factor: 4.287

10.  Septic arthritis in males with haemophilia.

Authors:  A A Ashrani; N S Key; J Michael Soucie; N Duffy; A Forsyth; S Geraghty
Journal:  Haemophilia       Date:  2008-02-21       Impact factor: 4.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.